Pharma BD Deal Intelligence
Ranks computed across 828 graded deals (Critic + Outcome Score both present).
FiercePharma framed the deal as 'Mallinckrodt bets $5.6B on Questcor and its controversial Acthar drug,' explicitly flagging the pricing-scrutiny and…
CNN investigation documented >$2B in Medicare spend on Acthar paired with millions in physician payments, surfacing the political and reputational tail risks…
Mallinckrodt shares 'skidded' after the company cut Acthar revenue guidance, validating earlier analyst skepticism that the $5.6B Questcor thesis was…
Source summaries from our enrichment pipeline; follow links for originals.
All 5 sources with sentiment breakdown →
Mallinckrodt agreed to acquire Questcor for approximately $5.6B in cash and stock ($30 cash plus 0.897 Mallinckrodt shares per Questcor share), centering the deal on Acthar Gel, which generated $761M in 2013 net sales. The transaction closed August 14, 2014 at a final value of approximately $5.8B and later drew federal scrutiny over Acthar pricing.
Assessment window: 5yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Mallinckrodt plc / Questcor Pharmaceuticals, Inc. (this deal) | 2014 | $5.6B | 18 |
| Mallinckrodt plc / Cadence Pharmaceuticals, Inc. | 2014 | $1.4B | 50 |
| Mallinckrodt plc / Therakos, Inc. | 2015 | $1.3B | 48 |
| Mallinckrodt plc / Ikaria, Inc. | 2015 | $2.3B | 37 |
| Mallinckrodt plc / Sucampo Pharmaceuticals, Inc. | 2017 | $1.2B | 19 |
| Mallinckrodt plc / InfaCare Pharmaceutical Corporation | 2017 | $425M | 12 |
| Amgen Inc. / Immunex Corporation | 2002 | $16.0B | 92 |
← Browse all deals · How we score deals
More: 2014 deals · Mallinckrodt plc deals · Immunology deals